Cancer API Market is Beneficial to Increase at a Reliable CAGR During Forecast to 2023

 

Market Overview:

The global cancer API market has been posting incremental growth over the recent past and is expected to register a moderate CAGR over the forecast period 2014-2023, reveals Market Research Future (MRFR) in a minutely analyzed research report. Various factors are influencing the growth of the global cancer API market. Surging demand for small molecule drugs is one of the preliminary factors boosting the growth of the market. The small molecule API market is undergoing a period of rapid change. Small molecules are predominating the pharmaceutical industry and account for nearly 80% of the pharmaceutical sales, indicating their relevance in the future of pharmaceuticals. Moreover, small molecules have made significant development in the field of cancer treatment. Moreover, a growing trend of outsourcing has been witnessed in the manufacture of APIs which is expected to contribute to themarket growth positively. The growth of the pharmaceutical industry in the developing countries is expected to provide an impetus to the growth of the cancer API market. The pharmaceutical industry in the developing nations as a whole is moving on a consolidation path which coupled with the growing number of mergers and acquisitions has proven to be beneficial for the growth of the cancer API market. Needless to say, towering cases of oncology diseases have been the major driving factor behind the growth of the global cancer API market. The market is also expected to benefit from improving the reimbursement landscape.

 

Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/6243

 

On the contrary, the growth of the market might be hindered by austerity measures in Europe. Ever since the economic downfall in Europe, Germany passed an act for restructuring the pharmaceutical market in statutory health insurance in an effort to curb its pharmaceutical spending. German drugs being the standard point of reference by healthcare providers have created severe pressure on drug manufacturers to decrease their cost of manufacturing. Low cure rates, poor efficacy, and side effects of cancer API are other possible restraints. However, the pharmaceutical industry is advancing rapidly in the backdrop of patent expiry of several popular drugs which expected to provide ample of growth opportunities to the Global Cancer API Market.

Competitive Landscape

Clovis Oncology,Ariad Pharmaceuticals (Takeda),Eli Lilly & Company,AstraZeneca plc,

Gilead Lifesciences,Bristol-Myers Squibb,F. Hoffman La Roche,BoehringerIngelheim,

Puma Biotech,Celgene,ExelixisInc,Novartis AG,Pfizer Inc,AbbVie Inc.,Eisai Ltd,Incyte Corporation,Bayer AG,TESARO, Inc., are the notable players operating in the global cancer API market.

 

Segmentation

The global cancer API market has been segmented based on Tinib, Rafenib, Parib, Lisib, Degib, and Ciclib. By tinib, teh market has been segmented into Ponatinib, Brigatinib, Ruxolitinib, Erlotinib, Alectinib, Cobimetinib, Neratinib, Osimertinib, Acalabrutinib, Bosutinib, Crizotinib, Axitinib, Sunitinib, Ceritinib, Imatinib, Lapatinib, Afatinib, Cabozantinib, Dasatinib, Ibrutinib, Lenvatinib, and Gefitinib. By Rafenib, the market has been segmented into Sorafenib, Regorafenib, Vemurafenib, Dabrafenib, and Enasidenib. By Parib, the market has been segmented into Olaparib, Rucaparib, and Niraparib. By Lisib, the market has been segmented into Idelalisib and Copanlisib. By Degib, the market has been segmented into Sonidegib and Vismodegib. The Ciclib category consists of Palbociclib, Ribociclib, and Abemaciclib.

 

Regional Analysis

The cancer API market is proliferating in the US owing to rise in FDA approvals and high investment in R&D of cancer APIs which is expected to provide lucrative opportunities for market expansion. In the meanwhile, Europe and Asia Pacific have not yet approved any small molecule API molecules which explain the limited growth of the market in these regions.

 

Industry Updates

·         In October 2018, Lonza, the Swiss biopharma CDMO partner, announced the further expansion of its highly potent API capacity for the support of antibody-drug conjugate (ADC) payload manufacturing. By the expansion, the company is ensuring critical supply for the treatment of cancer patients.

·         In August 2018, the US FDA recalled lots of generic blood pressure drug valsartan that contained the active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai. The contamination from the compound could put people at increased risk of cancer.

 

Comments

Post a Comment

Popular posts from this blog

Breathing Disorders And Treatments Market is Increasing at an Phenomenal CAGR During Forecast to 2023

  Market Overview: Breathing disorders are caused due to multiple factors that affect the respiratory system such as diseases such as allergies, infections and diseases like asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD) and others. Market Research Future (MRFR) has published a study report stating that the global breathing disorders and treatment market is registered to expand at a moderate pace and is anticipated to project high growth potential over the coming years.     Get a Free Sample @ https://www.marketresearchfuture.com/reports/breathing-disorders-treatment-market-1575     Market Drivers and Restraints: Increasing air pollution is one of the major causes that are triggering breathing disorders and respiratory diseases in highly populated regions. rise in prevalence of breathing disorders caused due to anthropogenic activities and other factors are inducing high demand for effective treatments all over the worl...
Read more

Dental Forceps Market is Rising at a Healthy CAGR of 5.2% During Forecast to 2024

Market Highlights: Numerous factors, such as the growing demand for dental forceps for performing several types of dental surgical procedures and the increasing number of dental practitioners and dental clinics, are anticipated to propel the growth of the market. Additionally, the growing incidence of dental diseases and the growing demand for cosmetic dentistry is likely to boost the growth of the market during the forecast period. According to the data published by the National Health Services (NHS), about 22.1 million adults were seen by an NHS dentist in the period, July 2016-July 2018. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/8012 The global Dental Forceps Market is anticipated to register a CAGR of 5.2 % during the forecast period of 2019 to 2024, with an estimated market value of USD 451.58 million in 2018. However, the availability of advanced dental equipment and limited reimbursement for dental surgeries are som...
Read more

Dental Forceps Market is Analytically Rising at a Healthy ACGR of 5.2% During Forecast to 2024

  Market Highlights: The global Dental Forceps Market is anticipated to register a CAGR of 5.2 % during the forecast period of 2019 to 2024, with an estimated market value of USD 451.58 million in 2018. However, the availability of advanced dental equipment and limited reimbursement for dental surgeries are some factors that may hinder the market growth during the assessment period. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/8012 Numerous factors, such as the growing demand for dental forceps for performing several types of dental surgical procedures and the increasing number of dental practitioners and dental clinics, are anticipated to propel the growth of the market. Additionally, the growing incidence of dental diseases and the growing demand for cosmetic dentistry is likely to boost the growth of the market during the forecast period. According to the data published by the National Health Services (NHS), about 22....
Read more